首页> 美国卫生研究院文献>BMC Pharmacology Toxicology >Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

【2h】

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

机译：口服抗糖尿病药物治疗的2型糖尿病患者中沙格列汀使用的决定因素

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundThe patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use.

机译：背景在现实世界中，未知2型糖尿病（T2DM）患者使用沙格列汀的方式和决定因素。我们比较了沙格列汀的新引发剂与非二肽基肽酶-4（DPP-4）抑制剂口服抗糖尿病药（OAD）的新引发剂的T2DM患者的特征，并确定了与沙格列汀使用相关的因素。

著录项

期刊名称 BMC Pharmacology Toxicology
作者
M Elle Saine; Dena M Carbonari; Craig W Newcomb; Melissa S Nezamzadeh; Kevin Haynes; Jason A Roy; Serena Cardillo; Sean Hennessy; Crystal N Holick; Daina B Esposito; Arlene M Gallagher; Harshvinder Bhullar; Brian L Strom; Vincent Lo Re III;
展开▼
作者单位

展开▼
年(卷),期 2015(16),-1
年度 2015
页码 8
总页数 16
原文格式 PDF
正文语种
中图分类药学;
关键词
Diabetes mellitus Saxagliptin Dipeptidyl peptidase IV inhibitor Pharmacoepidemiology;

机译：糖尿病;沙格列汀;二肽基肽酶IV抑制剂;药物流行病学;

相似文献

外文文献
中文文献
专利

1. Evaluation of Receptor Activator of Nuclear Factor Kappa-B Ligand and Osteoprotegerin Levels in Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-diabetics (Sulfonylurea and Metformin) or Insulin: Bone Tissue Perspective [J] . Gumus Alper, Duz Muhammed Emin, Coskun Cihan, Nature reviews neuroscience . 2019,第2期

机译：用口服抗糖尿病（磺酰脲和二甲双胍）或胰岛素治疗2型糖尿病患者核因子Kappa-B配体和骨盆素水平的核因子κB-B配体和骨盆素水平的评价。
2. A study on adverse drug reactions of oral anti-diabetic agents in patients with type II diabetes mellitus in Hi-Tech Medical College and Hospital, Bhubneswar, Odisha, India [J] . Indrani Dey, Srikanta Mohanty, Anju Prasad, International Journal of Basic & Clinical Pharmacology . 2019,第5期

机译：印度奥里萨邦布内斯瓦尔高科技医学院和医院的II型糖尿病患者口服抗糖尿病药的药物不良反应研究
3. Health Care Costs Associated With Treatment Modification in Type 2 Diabetes Mellitus Patients Taking Oral Anti-diabetic Drugs [J] . Girishanthy KrishnarajahMPHMBA/MS Managed care . 2011,第6期

机译：服用口服抗糖尿病药的2型糖尿病患者与治疗调整相关的医疗保健费用
4. A series of open-label studies comparing various formulations of orally administeredinsulin (Oralin) in patients with Type -1 Diabetes Mellitus (DM) [C] . Jaime Guevara-Aguirre, Marco Guevara, Jeannette Saavedra Annual meeting exposition of the Controlled Release Society . 2005

机译：一系列开放标签研究比较了-1型糖尿病（DM）患者口服胰岛素（Oralin）的各种配方
5. Anti-diabetic treatment and cancer occurrence among patients with type II diabetes mellitus. [D] . Qiu, Hong. 2011

机译：II型糖尿病患者的抗糖尿病治疗和癌症发生。
6. Adherence to anti-diabetic drugs among patients with Type 2 diabetes mellitus at Muhimbili National Hospital Dar es Salaam Tanzania- A cross-sectional study [O] . Godfrey Mutashambara Rwegerera 2014

机译：坦桑尼亚达累斯萨拉姆Muhimbili国家医院的2型糖尿病患者对抗糖尿病药物的依从性-一项横断面研究
7. Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs [O] . 2015

机译：口服抗糖尿病药物治疗的2型糖尿病患者中沙格列汀使用的决定因素

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅